Dr Andrew Hill

Who Dr Andrew Hill is

Dr Andrew Hill is a Senior Visiting Research Fellow in the Department of Pharmacology and Therapeutics at the University of Liverpool. He graduated from Oxford University, trained at St Mary's Hospital London, and gained his PhD at the University of Amsterdam. He specialises in research on access to medicines, the safety and efficacy of new treatments, and the minimum costs of generic drug manufacture. He serves as a consultant adviser to the World Health Organisation on HIV/AIDS and is a member of the WHO Fair Pricing Committee, advising countries on controlling medicine prices. He has been quoted in UK press coverage on NHS drug pricing, including on pharmaceutical companies' engagement with NICE cost-effectiveness evaluations. His published work spans HIV antiretrovirals, COVID-19 treatment costs, and generic drug pricing, with papers in the New England Journal of Medicine, The Lancet, and Science.

References for this biography

1. 1.Andrew Hill – The Conversation — Role title (Senior Visiting Research Fellow), institution (Liverpool University), education (Oxford, St Mary's, Amsterdam PhD), WHO consultancy and Fair Pricing Committee membership, specialisation in access to medicines
2. 2.The NHS Drug Price Dilemma – Medscape, November 2025 — Current departmental affiliation (Department of Pharmacology and Therapeutics, University of Liverpool); quoted on Gilead/NICE and NHS drug access
3. 3.Prices for generic cancer drugs in the UK have soared – The Pharmaceutical Journal — UK press quotation on NHS generic drug price rises; role described as senior research fellow in pharmacology and therapeutics, University of Liverpool
4. 4.Andrew Hill author page – The Pharmaceutical Journal — Described as honorary senior visiting research fellow, Department of Translational Medicine, University of Liverpool; adviser to WHO
5. 5.Andrew Hill – Bangkok International Symposium on HIV Medicine — Background in antiretroviral development since 1992; adviser to Clinton Foundation and Bill & Melinda Gates Foundation; PhD Amsterdam University
6. 6.New analysis exposes path to affordable lenacapavir – EATG, 2025 — Co-authorship of Lancet analysis on generic lenacapavir production costs for HIV prevention
7. 7.Prices versus costs of medicines: WHO Fair Pricing Forum, 2019 — Presented at WHO Fair Pricing Forum on drug pricing transparency, representing University of Liverpool

Notable achievements

• Co-authored a Lancet analysis showing lenacapavir for HIV prevention could be generically produced for as little as $25 per person per year, roughly 1,000 times below its US list price. Source ↗
• Presented findings at the WHO Fair Pricing Forum on transparency in medicine prices versus production costs, representing Liverpool University. Source ↗
• Raised public and policy attention to NHS generic cancer drug price rises of up to 1,227% over five years, as reported in the Pharmaceutical Journal. Source ↗
• Named as adviser to the Clinton Foundation and the Bill and Melinda Gates Foundation, designing clinical trial programmes for antiretroviral dose optimisation. Source ↗

What Dr Andrew Hill has said

• “Why spend an extra £9bn a year on higher drug prices to protect drug exports to the US of only £5bn a year? The maths simply does not add up.”

  drugs expert at University of Liverpool · Hospital discharge / bed-blocking · 27 Aug 2026 · UK drug exports to US spared tariffs under deal critics say will cost NHS billions ↗

• “These low prices open the door to worldwide access to an essential medicine.”

  pharmacology department, Liverpool University · Diabetes · 27 Aug 2026 · Weight-loss jab could be made for $3 a month, study finds ↗

Where Dr Andrew Hill has been quoted

1. NHS to pay 25% more for innovative drugs after UK–US zero-tariff dealtheguardian.com · 27 Aug 2026
2. UK drug exports to US spared tariffs under deal critics say will cost NHS billionstheguardian.com · 27 Aug 2026
3. Weight-loss jab could be made for $3 a month, study findstheguardian.com · 27 Aug 2026

Related media coverage

Recent UK press coverage of their topics — not necessarily citing them directly.

• Severe Type 1 Diabetes Onset Linked to Later ComplicationsEMJ
• Tazbentetol shows retinal neuroprotection potential in diabetic mouse modelDrug Target Review
• UK start-up takes on Americans with cheaper diabetes devicesThe Times

Contact & links

• Websitehttps://theconversation.com/profiles/andrew-hill-896374
• Websitehttps://www.researchgate.net/profile/Andrew-Hill
• Staff pagehttps://pharmaceutical-journal.com/author/andrew-hill

Organisational contact points only, each taken from a page the organisation publishes itself. No personal or direct contact details are held or shown.